Stay updated with breaking news from Mapi Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Viatris Inc (NASDAQ: VTRS) reported Q2 FY23 sales of $3.91 billion, up 2% on a divestiture-adjusted operational basis, marginally higher the
:max_bytes(150000):strip_icc()/GettyImages-1244663015-de666d27c3e54aa199e583bd5f8dff21.jpg)
Viatris shares advanced after the drugmaker posted better-than-expected results, said it will announce one or more divestitures this quarter, and indicated the FDA agreed to consider approval of its new multiple sclerosis treatment produced with Israel’s Mapi Pharma.
:max_bytes(150000):strip_icc()/GettyImages-1247204666-8127694cfcd844578195c6eeb7ea8a5e.jpg)
U.S. equities were higher at midday on Monday, Aug. 7, 2023, after the latest earnings reports and ahead of key inflation data due later in the week.
The FDA has accepted for review the NDA for glatiramer acetate depot 40mg for the treatment of relapsing forms of multiple sclerosis.
/PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, and Mapi Pharma today announced that recent data from ongoing studies of GA Depot 40...